Activation of the PPARγ/RXRα signaling pathway has been shown to inhibit cell growth, decrease tumor invasiveness, and reduce the production of pro-inflammatory cytokines in different cancer types, including colon, lung, pancreatic, prostate, and breast cancers (Figure 6) (Kubota et al., 1998; Sarraf et al., 1998; Motomura et al., 2000; Bonofiglio et al., 2009). This evidence concerns the gene PPARG and breast carcinoma.